I doubt this will get much press either way. No one really seems to care about hearing loss and tinnitus. There are breakthrough articles all the time if we read the news, but they always have the disclaimer that it could lead to something. Didn't GenVec come out and say that their CGF166 helped some people... and nothing happened. I don't see anything that Frequency Therapeutics develops threatening them. We still don't know what the outcome will be of the trials. Is a 10 dB gain enough to warrant not getting a hearing aid? Maybe, maybe not. You are still risking money unless you know the outcome of the trial. The outcome would have to be really really good and even then they would need to have a clear path moving forward to getting it approved. Even then I'm not sure it would do much unless FX-322 takes you back to 100 percent. As mentioned this is targeted toward moderate/mild loss. If it could put profound people into the moderate range then they would be candidates for hearing aids, this could open up business for them as well. Either way, I don't think this is a stock play.